Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Managing Advanced Stages of Friedreich’s Ataxia: Challenges and Emerging Therapeutic Avenues : Episode 3
Engaging mFARS Scale to Monitor Friedreich Ataxia Progression
An expert in Friedreich's ataxia evaluates the mFARS (modified Friedreich's Ataxia Rating Scale) measurement tool, highlighting its advantages and limitations, while also exploring alternative assessment methods for tracking disease progression.
EP: 1.Friedreich Ataxia: Addressing Treatment Objectives and Comorbidities
EP: 2.Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy
Now Viewing
EP: 3.Engaging mFARS Scale to Monitor Friedreich Ataxia Progression
EP: 4.Managing Adverse Events in Novel Friedreich’s Ataxia Therapy
EP: 5.Examining Trial Data on Omaveloxolone Efficacy
EP: 6.Promising Therapy Approaches for Advanced Friedreich Ataxia
EP: 7.Friedreich Ataxia: Looking Forward at the Treatment Landscape
EP: 8.Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia
EP: 9.Diagnosis of Friedreich Ataxia
EP: 10.Impact of Friedreich Ataxia on Quality of Life
EP: 11.Clinical Utility of the Modified Friedreich Ataxia Rating Scale
EP: 12.Comorbidities and Complications Associated With Friedreich Ataxia
EP: 13.Challenges Associated With Friedreich Ataxia
EP: 14.Future Considerations for Friedreich Ataxia
- The mFARS measurement tool is frequently reserved for clinical trials due to its time-consuming nature. What alternative tool do you employ to monitor disease progression, and have you observed any shifts in these metrics following the approval of omaveloxolone?
- What is the clinical value of omaveloxolone in patients with wheelchair dependence?
Related Videos
Related Content
